<生产厂家价格>

卢非酰胺

卢非酰胺用途

Rufinamide(E 2080; CGP 33101; RUF 331)是新型镇痫化合物,可作为Lennox-Gastaut综合症的辅助治疗。

卢非酰胺名称

[ CAS 号 ]:
106308-44-5

[ 中文名 ]:
卢非酰胺

[ 英文名 ]:
Rufinamide

[中文别名 ]:

[英文别名 ]:

Rufinamide
Banzel
Inovelon

卢非酰胺生物活性

[ 描述 ]:

Rufinamide(E 2080; CGP 33101; RUF 331)是新型镇痫化合物,可作为Lennox-Gastaut综合症的辅助治疗。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

天然产物 >> 生物碱

研究领域 >> 神经疾病

[参考文献]

[1]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72.

[2]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20.

[相关活性小分子]

卢非酰胺物理化学性质

[ 密度 ]:
1.5±0.1 g/cm3

[ 沸点 ]:
473.8±55.0 °C at 760 mmHg

[ 熔点 ]:
232-234?C

[ 分子式 ]:
C₁₀H₈F₂N₄O

[ 分子量 ]:
238.193

[ 闪点 ]:
240.4±31.5 °C

[ 精确质量 ]:
238.066620

[ PSA ]:
73.80000

[ LogP ]:
0.05

[ 外观性状 ]:
白色粉末

[ 蒸汽压 ]:
0.0±1.2 mmHg at 25°C

[ 折射率 ]:
1.635

[ 储存条件 ]:
−20°C

[ 水溶解性 ]:
DMSO: soluble9mg/mL

卢非酰胺MSDS

详细MSDS(安全技术说明书)

卢非酰胺安全信息

[ 危害码 (欧洲) ]:
F,T

[ 风险声明 (欧洲) ]:
11-23/24/25-39/23/24/25-48-41-38-28

[ 安全声明 (欧洲) ]:
7-16-36/37-45-36/37/39-28-26-24/25

[ 危险品运输编码 ]:
UN 1648 3 / PGII

卢非酰胺文献

Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats.

Eur. J. Pharm. Sci. 68 , 106-13, (2015)

Rufinamide is a third-generation antiepileptic drug, approved recently as an orphan drug for the treatment of Lennox-Gastaut syndrome. Although extensive research was conducted, its pharmacokinetics i...

Toxicological screening of human plasma by on-line SPE-HPLC-DAD: identification and quantification of basic drugs and metabolites.

Biomed. Chromatogr. 29 , 935-52, (2015)

An automated multi-analyte screening method for the identification and quantification of 92 drugs and metabolites based on on-line solid-phase extraction-high-performance liquid chromatography-diode a...

Rufinamide for the treatment of Lennox-Gastaut syndrome.

Expert Opin. Pharmacother. 12(5) , 801-6, (2011)

Lennox-Gastaut syndrome (LGS) is a severe treatment-resistant childhood-onset epilepsy. This review examines the role of the new drug rufinamide for the treatment of LGS.MEDLINE and Google Scholar sea...

更多文献

卢非酰胺

卢非酰胺用途

卢非酰胺名称

卢非酰胺生物活性

卢非酰胺物理化学性质

卢非酰胺MSDS

详细MSDS(安全技术说明书)

卢非酰胺安全信息

卢非酰胺文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

相关化合物